Tesamorelin is a growth-hormone-releasing factor analog with a specific FDA-approved medical use. Because it is frequently discussed online alongside weight-loss and body-composition peptides, understanding what it is actually approved to treat is essential.
Tesamorelin stimulates endogenous growth-hormone release. The FDA-approved tesamorelin product EGRIFTA SV is indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. Its prescribing information specifically states that it is not indicated for weight-loss management.
Tesamorelin should not be positioned as an alternative version of semaglutide or tirzepatide. These medications act through different pathways, have different approved indications and require different safety considerations. For obesity treatment, medication selection should be based on diagnosis, medical history, contraindications, goals and current evidence.
Compare our educational resources on Semaglutide, Tirzepatide, and Peptide Therapy.
Tesamorelin has important contraindications, warnings and monitoring considerations. The FDA labeling includes warnings involving active malignancy, elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity reactions. Treatment decisions require an appropriate clinician and should not be based on cosmetic or online marketing claims.
Review FDA prescribing information for EGRIFTA SV.
Yes, an FDA-approved tesamorelin product exists for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
No. FDA labeling specifically states that EGRIFTA SV is not indicated for weight-loss management.
Its approved indication concerns excess abdominal fat in adults with HIV and lipodystrophy. Evidence from that population should not be automatically generalized to people seeking routine obesity treatment or cosmetic fat loss.
Appropriate monitoring depends on the indication and patient. FDA labeling includes monitoring considerations for IGF-1 and glucose-related effects, among other safety issues.
Medical note: This page is educational. FDA-approved indication does not mean a medication is appropriate for every patient or for an unapproved purpose.
